With each passing week, we are seeing more and more advances in psychedelic research from the scientific and medical fields. As the body of research continues to grow, Truffle Report has compiled a roundup of major medical and scientific news from March 21 to March 26 2021, making it easier for you to track these ongoing developments.
Lab Expansion Project in Nanaimo to Aid Magic Mushroom, Psychedelics Research
March 21 , 2021 – Numinus Wellness Inc., based in British Columbia, is expected to add a 7,500-square-foot addition to its existing complex by the end of 2021. This expansion will strengthen the facility’s research capacity.
New Research Could Help Predict Acute Reactions to Psychedelic Drugs
March 22, 2021 – New research from Ohio State University has identified personality traits that have been associated with positive and negative experiences on psychedelics in previous studies. This information could help predict how future patients will respond to the drugs.
Psychedelic Joint Venture Between Mycotopia Therapies and Natural MedTech Brings Research and Drug Development to Test Active Ingredient In Psychedelics
March 22, 2021 – Mycotopia Therapies, (OTC Pink: TWGL) (the “Company”), a Florida based company focused on psychedelic therapies, announced this week it has created PsyBioMed – Australia and that they have entered into a letter of intent to jointly conduct clinical trials in Australia using psychedelics to treat mental illnesses. This partnership intends to obtain licences and permits to legally possess, supply, sell, and manufacture psychedelics in Australia.
UW–Madison Pioneers Master’s Program in Therapeutic Use of Psychoactive Drugs
March 23, 2021 – The University of Wisconsin–Madison School of Pharmacy will enroll students in their new online MS in Pharmaceutical Sciences: Psychoactive Pharmaceutical Investigation this fall. This is the first and only master’s program of its kind in the United States.
XPhyto Therapeutics Diversifies Into Psychedelics With New Labs
March 25, 2021 – XPhyto Therapeutics, a Vancouver based corporation, is currently expanding into psychedelic medicines by launching XPhyto Laboratories. The company’s focus involves the formulation of psychedelic compounds into mood-improving and therapeutic pharmaceutical drugs. XPhyto’s psychedelic research is led by German psychedelic researcher Professor Raimar Löbenberg.
